What do patients with substance use disorders know about their medication? A cross-sectional interview-based study

药物滥用患者对他们的药物了解多少?一项基于横断面访谈的研究

阅读:1

Abstract

PURPOSE: This study investigates the medication knowledge of patients with substance use disorders (SUDs) treated at a psychiatric clinic in northern Germany, aiming to identify gaps in understanding and to enhance patient safety, particularly concerning ATC group A drugs. SETTING: The study was conducted in the Department of Psychiatry, Social Psychiatry, and Psychotherapy at Hannover Medical School, Germany. DESIGN: A cross-sectional, interview-based study using a convenience sample of 100 patients was conducted between March 2023 and April 2024. PARTICIPANTS: The cohort included patients with SUDs who had been hospitalized for at least 72 hours, regularly took at least one medication in addition to withdrawal drugs, and who displayed no cognitive impairments. Participants had a median age of 46.5 years; 62% were male. INTERVENTION: Patients were interviewed using a customized questionnaire addressing knowledge of drug name, indication, dosage, and frequency of application. The questionnaire also assessed the sources of medication knowledge and patient opinions on their medication regimen. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was the average medication knowledge score (range 0-6). Secondary measures included differences in knowledge across drug groups, sources of information, and demographic influences. RESULTS: The median medication knowledge score was 3.8 out of 6. Knowledge was significantly lower for ATC group A drugs compared to groups B, C, and N (p < 0.001). No significant differences were observed between men and women nor between age groups. Hospital physicians were the primary information source for 40% of patients. Most participants (84%) considered their medication regimen adequate. CONCLUSION: Patients with SUDs demonstrated suboptimal medication knowledge, particularly regarding ATC group A drugs. Future strategies should prioritize patient education and enhanced physician engagement to improve understanding and adherence, ultimately fostering better therapeutic outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。